DEAR EDITOR, Higher rates of conjunctivitis have been reported in patients with atopic dermatitis (AD) treated with dupilumab, an anti-interleukin (IL)-4Ra antibody inhibiting IL-4 and IL-13, vs. patients treated with placebo. 1 However, the exact pathomechanism has not been clarified. Given the necessity for optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in patients with AD.
blocking IL-13, dupilumab treatment may lead to GC hypoplasia, as IL-4Ra is expressed on conjunctival epithelium. This might result in decreased mucin production, subsequent tear film instability and mucosal epithelial barrier dysfunction, leading to conjunctival inflammation in a subpopulation of (predisposed) patients with AD. Clinically, the loss of GC-produced factors may result in dry eyes, as was reported by all patients, and subsequently irritative conjunctivitis. As in this study biopsies were performed after initiation of dupilumab, GC scarcity might already be present before dupilumab treatment, although patients did not experience ocular symptoms at start of treatment. Our histopathological findings do not correspond with the histopathology of atopic keratoconjunctivitis and allergic conjunctivitis, which is associated with an increased GC density and increased mucus production, probably due to IL-13 overexpression. 5, 6 Dupilumab treatment might theoretically be beneficial in these typical Th2-mediated ocular surface diseases.
It has been proposed that dupilumab treatment could increase Demodex numbers in hair follicles, causing ocular rosacea-like disease. 7 Ocular rosacea is a Th17-driven disease characterized by an inflammatory cell infiltrate, mainly consisting of CD4 + T cells, but not eosinophils. 8 The unique combination of low conjunctival GC numbers accompanied by numerous lymphocytes and eosinophils found in this study may imply a new entity of conjunctivitis in dupilumab-treated patients with AD.
Only patients with new onset of conjunctivitis symptoms or worsened symptoms in cases of pre-existing conjunctivitis were included in this study; these probably do not represent all conjunctivitis cases during dupilumab treatment. In daily practice, we experience some patients reporting improvement of conjunctivitis symptoms during dupilumab treatment, underlining the heterogeneity of the conjunctivitis.
Limitations of this study are small sample size, and collection of conjunctival biopsies at one single time point. Therefore, dynamic differences in histopathological features before and during dupilumab treatment could not be studied. Nevertheless, the histopathological features and findings were very consistent, and constitute a first clue in the underlying pathomechanism of dupilumab-associated conjunctivitis. However, the exact pathomechanism of this new entity of conjunctivitis could not be fully elucidated.
In conclusion, this study found a remarkable scarcity of conjunctival GCs accompanied by an inflammatory T-cell-and eosinophilic infiltrate in patients with AD with conjunctivitis during dupilumab treatment. We hypothesize that the IL-13 blocking effect of dupilumab might lead to reduction of GCs and mucin production in a subpopulation of patients with AD, which may potentially result in irritative conjunctivitis. A prospective study further characterizing conjunctivitis in patients with AD before and during dupilumab treatment will start soon.
